Dicliripariside A is primarily used in pharmaceutical research for its potential anti-inflammatory and immunomodulatory properties. It has shown activity in preclinical studies targeting chronic inflammatory conditions, including autoimmune skin disorders. Due to its unique structural profile, it serves as a lead compound in the development of topical formulations aimed at reducing dermal inflammation with minimal systemic absorption. Additionally, it is being investigated for its role in modulating specific cytokine pathways, which may offer therapeutic benefits in conditions like psoriasis and atopic dermatitis. Its application remains largely experimental, confined to laboratory and early-stage drug discovery settings.